PIPRA AG is a Swiss digital health innovator addressing neurocognitive diseases, beginning with a focus on a critical and vastly underserved healthcare challenge: Delirium. Delirium impacts 1 in 4 hospital patients over 60, dramatically increasing dementia risk by 14x and nursing home admissions by 6x. Despite costing healthcare systems 60% more than diabetes, delirium remains poorly managed and underrecognized.

 

PIPRA’s CE-certified, AI-driven solution provides hospitals with rapid, accurate, and cost-effective tools for delirium risk management already validated and in use across leading healthcare facilities in E.U. and U.S. Our technology enables hospitals to implement targeted preventive interventions, significantly improving patient outcomes, shortening hospital stays, and achieving avg savings of €2.5 million per 1,000 patients, demonstrated in peer-reviewed publications including "Age and Ageing", “BMJ” and "JAMA Network Open."

 

With prestigious international awards, strategic global partnerships, and a clearly defined roadmap to scale, PIPRA is uniquely positioned to become the global market leader in delirium management.